WO2007050631A3 - Dosage form with coated active - Google Patents

Dosage form with coated active Download PDF

Info

Publication number
WO2007050631A3
WO2007050631A3 PCT/US2006/041524 US2006041524W WO2007050631A3 WO 2007050631 A3 WO2007050631 A3 WO 2007050631A3 US 2006041524 W US2006041524 W US 2006041524W WO 2007050631 A3 WO2007050631 A3 WO 2007050631A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage forms
coated active
dosage form
active ingredient
orally dissolvable
Prior art date
Application number
PCT/US2006/041524
Other languages
French (fr)
Other versions
WO2007050631A2 (en
Inventor
Derek Moe
Zepeda Manuel A Vega
Original Assignee
Cima Labs Inc
Derek Moe
Zepeda Manuel A Vega
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc, Derek Moe, Zepeda Manuel A Vega filed Critical Cima Labs Inc
Publication of WO2007050631A2 publication Critical patent/WO2007050631A2/en
Publication of WO2007050631A3 publication Critical patent/WO2007050631A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Abstract

The present invention relates to orally dissolvable/disintegrable dosage forms adapted for direct oral dosing comprising at least one coated active ingredient formed by co-spray drying an active ingredient and a coating. These dosage forms are harder than known orally dissolvable disintegrable dosage forms and have advantages in terms of manufacturing and storage costs.
PCT/US2006/041524 2005-10-25 2006-10-24 Dosage form with coated active WO2007050631A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73016805P 2005-10-25 2005-10-25
US60/730,168 2005-10-25

Publications (2)

Publication Number Publication Date
WO2007050631A2 WO2007050631A2 (en) 2007-05-03
WO2007050631A3 true WO2007050631A3 (en) 2007-11-01

Family

ID=37898582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/041524 WO2007050631A2 (en) 2005-10-25 2006-10-24 Dosage form with coated active

Country Status (1)

Country Link
WO (1) WO2007050631A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CN102885791B (en) * 2012-09-24 2015-03-04 浙江万晟药业有限公司 Method for preparing fexofenadine hydrochloride orally disintegrating tablet
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
KR102017550B1 (en) 2013-11-13 2019-09-03 내셔널 디펜스 에듀케이션 앤드 리서치 파운데이션 New acetaminophen compound composition without side effect to liver
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (en) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Liquid-filled dosage form to prevent immediate release abuse
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
CN106511286B (en) * 2016-10-27 2019-12-20 四川省百草生物药业有限公司 Famciclovir tablet with high stability and preparation method thereof
JP6858729B2 (en) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ New acetaminophen complex composition with no side effects on the liver

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631284A (en) * 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
US4710519A (en) * 1985-09-30 1987-12-01 Basf Corporation Process for preparing spray dried acetaminophen powder and the powder prepared thereby
US4904477A (en) * 1987-07-08 1990-02-27 American Home Products Corporation Spray dried ibuprofen compositions
US4952402A (en) * 1984-10-30 1990-08-28 Elan Corporation, P.L.C. Controlled release powder and process for its preparation
WO2000051568A1 (en) * 1999-03-01 2000-09-08 Ethypharm Orally dispersible tablet with low friability and method for preparing same
WO2001089484A2 (en) * 2000-05-22 2001-11-29 Verion, Inc. Method for increasing the compressibility of poorly binding powder materials

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952402A (en) * 1984-10-30 1990-08-28 Elan Corporation, P.L.C. Controlled release powder and process for its preparation
US4631284A (en) * 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
US4710519A (en) * 1985-09-30 1987-12-01 Basf Corporation Process for preparing spray dried acetaminophen powder and the powder prepared thereby
US4904477A (en) * 1987-07-08 1990-02-27 American Home Products Corporation Spray dried ibuprofen compositions
WO2000051568A1 (en) * 1999-03-01 2000-09-08 Ethypharm Orally dispersible tablet with low friability and method for preparing same
WO2001089484A2 (en) * 2000-05-22 2001-11-29 Verion, Inc. Method for increasing the compressibility of poorly binding powder materials

Also Published As

Publication number Publication date
WO2007050631A2 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
WO2007050631A3 (en) Dosage form with coated active
JP2009506080A5 (en)
WO2007052299A3 (en) Controlled release formulation
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
BR0309142A (en) Oral pharmaceutical formulation in aqueous suspension form of microcapsules allowing modified release of active ingredient (s)
WO2008048963A3 (en) Natural compositions for killing parasites on a companion animal
FR2891459B1 (en) MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE INGREDIENT AND ORAL GALENIC FORM COMPRISING THE SAME
WO2010123919A3 (en) Piperidine inhibitors of janus kinase 3
WO2009100441A3 (en) Depot formulations
WO2010019587A3 (en) Oral care composition comprising capsules
JP2009524695A5 (en)
WO2010038237A3 (en) Compositions exhibiting delayed transit through the gastrointestinal tract
ZA200804427B (en) Nanoparticulate active ingredient formulations
JP2008515980A5 (en)
WO2007090113A3 (en) Use of antifungal compositions to treat upper gastrointestinal conditions
WO2009045795A3 (en) Galenical formulations of aliskiren and valsartan
EP2180024A4 (en) Hydrophilic film-forming composition, spray composition, and hydrophilic member using the same
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
JP2011500876A5 (en)
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
WO2009139504A3 (en) A solid pharmaceutical formulation
IL208151A0 (en) Long-term stable pharmaceutical preparation having the active ingredient glycerol trinitrate
WO2009006299A3 (en) Multi-particulate systems
WO2009136884A3 (en) Metformin-pioglitazone formulation with antihyperglycemic effects

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06817354

Country of ref document: EP

Kind code of ref document: A2